Current approaches to the treatment of Candida albicans infections

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 2, 2001, Pages 269-282

  Burt, E T ^a  

^a Des Moines University College of Osteopathic Medicine   (United States)

Author keywords

1 3 glucan synthase inhibitors; Antifungals; Azoles; Candida albicans; Echinocandins; Macrolides; Polyenes

Indexed keywords

ACRIDINE DERIVATIVE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CRAMBESCIDIN; DANSYLCADAVERINE; ECHINOCANDIN B DERIVATIVE; ECONAZOLE; ERYTHROMYCIN DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; FUNGUS VACCINE; HETEROCYCLIC COMPOUND; ITRACONAZOLE; KETOCONAZOLE; LACTOFERRIN; MACROLIDE; MICONAZOLE; NAFTITINE; NATURAL PRODUCT; NYSTATIN; PARASIN; POLYENE; PROTEGRIN; PROTEIN DERIVATIVE; PYRROLE DERIVATIVE; RAPAMYCIN DERIVATIVE; SPONGISTATIN DERIVATIVE; TERBINAFINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER THERAPY; CANDIDA ALBICANS; CANDIDIASIS; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG SOLUBILITY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LD 50; LIVER TOXICITY; MOUSE; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; PATENT; RAT; REVIEW; SIDE EFFECT; SKIN MANIFESTATION;

EID: 0035150578     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.2.269     Document Type: Review

References (36)

1. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit
2. Candidemia in a tertiary care hospital: Epidemiology, risk factors and predictors of mortality
3. Candidemia in non-neutropenic critically ill patients: Analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU
4. Nosocomial candidemia: Risk factors and attributable mortality
5. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: A multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients
6. Clinical, cellular and molecular factors that contribute to antifungal drug resistance
7. Adverse drug reactions to systemic antifungals. Prevention and management
8. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans
9. Increased mRNA levels of ERG16, CDR and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus
10. Molecular mechanisms of drug resistance in fungi
11. Cytochrome P-450-dependent 14 alpha-sterol demethylase of Candida albicans and its interaction with azole antifungals
12. Characterization of Saccharomyces cerevisiae CYP61, sterol delta22-desaturase and inhibition by azole antifungal agents
13. Sterol 22-desaturase, cytochrome P45061, possesses activity in xenobiotic metabolism
14. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents
15. Anti-Candida drugs-the biochemical basis for their activity
16. Molecular mechanisms of azole resistance in fungi
17. Antimicrobial peptides as potential new antifungals
18. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors
19. Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections
20. Probiotic effects of feeding heat-killed Lactobacillus acidophilus and Lactobacillus casei to Candida albicans-colonized immunodeficient mice
21. Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus
22. Parasin I, an antimicrobial peptide derived from histone H2A in the catfish, Parasilurus asotus
23. Development of protegrins for the treatment and prevention of oral mucositis: Structure-activity relationships of synthetic protegrin analogues
24. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis
25. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
26. Cationic antimicrobial peptides: Towards clinical applications
27. [Central nervous system mycotic infections]
28. The Ess1 prolyl isomerase is linked to chromatin remodeling complexes and the general transcription machinery
29. Identification and characterization of TUP1-regulated genes in Candida albicans
30. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates
31. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice
32. [Advances in the diagnosis of mycoses. New tests detect Candida infections]
33. Protease inhibitors: Current status and future prospects
34. The effect of estradiol on Candida albicans growth
35. Candida albicans morphogenesis is Influenced by estrogen
36. Protective effect of the selective estrogen receptor modulator LY117018 on rat vaginal Candida albicans colonization